Glenmark Pharmaceuticals Q4 Results: Company Swings To Profit
The company declared a dividend of Rs 2.5 apiece with a face value of Rs 2 each for fiscal 2025.
Glenmark Pharmaceuticals Ltd. swung to profit in the quarter ended March, but missed analysts' estimates.
The company posted a profit of Rs 4.7 crore in the fourth quarter as compared to Rs 1,218-crore loss in the year-ago period, according to an exchange filing on Friday. Analysts tracked by Bloomberg had estimated a net profit of Rs 344 crore.
Glenmark Q4 Highlights (Consolidated, YoY)
Revenue up 6.3% at Rs 3,256 crore versus Rs 3,063 crore. (Bloomberg estimate: Rs 3,365 crore)
Ebitda up 11% at Rs 561 crore versus Rs 504 crore. (Bloomberg estimate: Rs 3,365 crore)
Margin at 17.2% versus 16.5%. (Bloomberg estimate: Rs 3,365 crore).
Net profit at Rs 4.7 crore versus a loss of Rs 1,218 crore. (Bloomberg estimate: Rs 344 crore)
Dividend
The company declared a dividend of Rs 2.5 apiece with a face value of Rs 2 each for fiscal 2025. It is subject to approval at the annual general meeting. The dividend will be paid within 30 days of the AGM.
The firm may disburse up to Rs 70.5 crore in dividend payouts to their shareholders. Retail Investors may be paid up to Rs 8.6 crore in dividend payouts.
Shares of Glenmark Pharma closed 0.66% lower at Rs 1,420.2 apiece on the NSE, compared to a 0.99% rise in the benchmark Nifty.
